Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD489 maintenance in Binge Eating Disorder
NCT02009163Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in binge eating disorder (BED) comparing Lisdexamfetamine dimesylate with Placebo (2 arms). Primary endpoint: Time to Relapse From Date of Randomization to Endpoint of The Randomized-withdrawal Period at 26 weeks. Started Jan 2014; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT02009163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009163.